A protocol for the economic evaluation of the Smoking Cessation in Pregnancy Incentives Trial (CPIT III)

Mcmeekin, N., Sinclair, L., Bauld, L., Tappin, D. M. , Mitchell, A. and Boyd, K. A. (2020) A protocol for the economic evaluation of the Smoking Cessation in Pregnancy Incentives Trial (CPIT III). BMJ Open, 10, e038827. (doi: 10.1136/bmjopen-2020-038827)

[img] Text
223757.pdf - Published Version
Available under License Creative Commons Attribution.

464kB

Abstract

Introduction: Smoking results in an average 10-year loss of life, but smokers who permanently quit before age 40 can expect a near normal lifespan. Pregnancy poses a good opportunity to help women to stop; around 80% of women in the UK have a baby, most of whom are less than 40 years of age. Smoking prevalence during pregnancy is high: 17%–23% in the UK. Smoking during pregnancy causes low birth weight and increases the risk of premature birth. After birth, passive smoking is linked to sudden infant death syndrome, respiratory diseases and increased likelihood of taking up smoking. These risks impact the long-term health of the child with associated increase in health costs. Emerging evidence suggests that offering financial incentives to pregnant women to quit is highly cost effective. This protocol describes the economic evaluation of a multi-centre randomised controlled trial (Cessation in Pregnancy Incentives Trial III, CPIT III) designed to establish whether offering financial incentives, in addition to usual care, is effective and cost effective in helping pregnant women to quit. Methods and analysis: The economic evaluation will identify, measure and value resource use and outcomes from CPIT III, comparing participants randomised to either usual care or usual care plus up to £400 financial incentives. Within-trial and long-term analyses will be conducted from a National Health Service and Personal Social Services perspective; the outcome for both analyses will be quality adjusted life-years measured using EQ-5D-5L. Patient level data collected during the trial will be used for the within-trial analysis, with an additional outcome of cotinine validated quit rates at 34–38 weeks gestation and 6 months postpartum. The long-term model will be informed by data from the trial and published literature.

Item Type:Articles
Additional Information:Cancer research UK (C48006/A20863), Chief Scientist Office Scottish Government (HIPS/16/1), Health and Social Care Services Northern Ireland (COM/5352/17), Chest Heart & Stroke Northern Ireland (2019_09), Lullaby Trust (272), Scottish Cot Death Trust (no reference available), Public Health Agency NI (no reference available).
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Tappin, Professor David and Boyd, Dr Kathleen and Mcmeekin, Mrs Nicola
Authors: Mcmeekin, N., Sinclair, L., Bauld, L., Tappin, D. M., Mitchell, A., and Boyd, K. A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
College of Medical Veterinary and Life Sciences > Institute of Health and Wellbeing > Health Economics and Health Technology Assessment
Journal Name:BMJ Open
Publisher:BMJ Publishing Group
ISSN:2044-6055
ISSN (Online):2044-6055
Copyright Holders:Copyright © 2020 The Authors
First Published:First published in BMJ Open 10:e038827
Publisher Policy:Reproduced under a Creative Commons Licence

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
300299Smoking Cessation in Pregnancy Incentives Trial (CPIT): A phase III Randomised Controlled TrialDavid TappinCancer Research UK (CRUK)C48006/A20863Med - Child Health